Skip to main content
SpringerLink
Log in

In vitro evaluation of anticancer drugs in relation to development of drug resistance in the human tumor clonogenic assay

  • Original Articles
  • In Vitro Antitumor Activity, Human Tumor Clonogenic Assay, Drug Resistance
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

The efficacy of anticancer drugs against ovarian cancer, breast cancer, and colorectal cancer has been evaluated in vitro by the human tumor clonogenic assay developed by Hamburger and Salmon. The in vitro colony assay method used in this study is a minor modification of their method and was used in 83 patients with ovarian cancer, 47 patients with breast cancer, and 13 patients with colorectal cancer. The total numbers of assays performed in vitro were 258 for ovarian cancer, 87 for breast cancer, and 38 for colorectal cancer. The average chemosensitivity rates to single agents tested were 35% and 32% in the untreated patients with ovarian and breast cancer, respectivety. In contrast to this result, the chemosensitivity rate of the untreated patients with colorectal cancer was only 16%. Consisting the clinical efficacy of anticancer drugs against these tumors, these results suggest that there is a correlation between chemosensitivity in the human tumor clonogenic assay and clinical responsiveness. In this assay the chemosensitivity in specimens from ovarian cancer patients who had had prior chemotherapy was significantly lower than in those from nonpretreated patients (P0.05). This seems to indicate the development of drug resistance after treatment with anticancer drugs. These results suggest that the human tumor clonogenic assay is a useful tool for the evaluation of antitumor effects of drugs in vitro.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ahmann ER, Meyskens FL, Moon TE, Durie BGM, Salmon SE (1982) In vitro chemosensitivities of human tumor stem cells to the phase II drug 4′-(9-acridinylamino) methanesulfon-m-anisidide and prospective in vivo correlations. Cancer Res 42: 4495

    Google Scholar 

  2. Alberts DS, Chen HSG, Liu R, Himmelstein KJ, Mayersohn M, Perrier D, Gross J, Moon T, Broughton A, Salmon AE (1978) Bleomycin pharmacokinetics in man. I: Intravenous administration. Cancer Chemother Pharmacol 1: 177

    Google Scholar 

  3. Alberts DS, Chang SY, Chen HSG, Moon TE, Evans TL, Furner RL, Himmelstein K, Gross JF (1979) Kinetics of intravenous melphalan. Clin Pharmacol Ther 26: 73

    Google Scholar 

  4. Bachur NR, Riggs CE, Green MR, Langone JJ, Vunakis HV, Levine L (1977) Plasma adriamycin and daunorubicin levels by fluorescence and radioimmunoassay. Clin Pharmacol Ther 21: 70

    Google Scholar 

  5. Bertelsen CA, Sondak VK, Mann BD, Korn EL, Kern DH (1984) Chemosensitivity testing of human solid tumors. A review of 1582 assays with 258 clinical correlations. Cancer 53: 1240

    Google Scholar 

  6. Bradley EC, Issell BF, Hellman R (1984) The human tumor colony-forming chemosensitivity assay. A biological and clinical review. Invest New Drugs 2: 59

    Google Scholar 

  7. D'Incalci M, Sessa C, Belloni C, Morasca L, Garattini S (1979) Hexamethylmelamine (HMM) and pentamethylmelamine (PMM) levels in plasma and ascites after oral administration to ovarian cancer patients. Proc Am Assoc Cancer Res 20: 46

    Google Scholar 

  8. D'Incalci M, Sessa B, Mangioni C (1981) Influence of ascites on the pharmacokinetics of hexamethylmelamine and N-demethylated metabolites in ovarian cancer patients. Eur J CanCer Clin Oncol 17: 1331

    Google Scholar 

  9. Finn C, Sadée W (1975) Determination of 5-fluorouracil (NSC-19893) plasma levels in rats and man by isotope dilution-mass fragmentography. Cancer Chemother Rep [1] 59: 279

    Google Scholar 

  10. Fujita H (1969) Absorption, distribution and excreation of bleomycin. J Jpn Cancer Ther 4: 336

    Google Scholar 

  11. Hamburger AW, Salmon SE (1977a) Primary bioassay of human myeloma stem cells. J Clin Invest 60: 846

    Google Scholar 

  12. Hamburger AW, Salmon SE (1977b) Primary bioassay of human tumor stem cells. Science 197: 461

    Google Scholar 

  13. Inagaki J, Ogawa M, Horikoshi N, Inoue K (1983) Combination chemotherapy with cyclophosphamide, adriamycin, cisplatin and 5-fluorouracil for advanced ovarian cancer. In: Ogawa M, Muggia FJ, Rozencweig M (eds) Adriamycin. Excepta Medica, Amsterdam, p 243. (International congress series, no. 629).

    Google Scholar 

  14. Inoue K, Arakawa M, Ogawa M, Inagaki J, Horikoshi N, Ezaki K, Aiba K, Domyo M, Miyamoto H, Ikeda K (1982) Colony formation of solid tumor in in vitro colony assay. Jpn J Cancer Chemother 9: 2128

    Google Scholar 

  15. Inoue K, Arakawa M, Miyamoto H, Ogawa M (1983) Activity of 4′-0-tetrahydropyranyladriamycin hydrochloride (THP-ADM) in a human tumor cloning system. Invest New Drugs 1: 271

    Google Scholar 

  16. Inoue K, Arakawa M, Miyamoto H, Ogawa M, Inagaki J, Horikoshi N, Ikeda K, Usui N, Nakada H, Adachi K, Mukaiyama T (1984a) Colony growth by various malignant cells of cancer patients on in vitro colony assay. Jpn J Cancer Ther 19: 1456

    Google Scholar 

  17. Inoue K, Ogawa M, Inagaki J, Horikoshi N, Miyamoto H, Ikeda K, Usui N, Nakada H, Adachi K (1984b) A randomized trial of adriamycin, cyclophosphamide, ftorafur (ACF) and adriamycin, cyclophosphamide, ftorafur, methotrexate (ACFM) in patients with advanced breast cancer. Cancer Chemother Pharmacol 13: 95

    Google Scholar 

  18. Mattox DE, Von Hoff DD (1980) In vitro stem cell assay in head and neck squamous carcinoma. Am J Surg 140: 527

    Google Scholar 

  19. Miyamoto H, Inoue K, Arakwa M, Ogawa M (1982) Chemosensitivity of adriamycin, mitomycin C and bleomycin with in vitro colony assay. Jpn J Cancer Chemother 9: 1921

    Google Scholar 

  20. Ogawa M, Miyamoto H, Inagaki J, Horikoshi N, Inoue K, Ikeda K, Usui N, Nakada H (1983) Phase I clinical trials of a new anthracycline, 4′-0-tetrahydropyranyladriamycin. Jpn J Cancer Chemother 10: 129

    Google Scholar 

  21. Okumura S, Deguchi T, Nakamizo N (1975) Studies on the physiological disposition and pharmacokinetics of 7-N(p-hydroxyphenyl)-mitomycin C. Jpn J Antibiot 35: 1967

    Google Scholar 

  22. Patton TF, Himmelstein KJ, Belt R, Bannister SJ, Sternson LA, Repta AJ (1978) Plasma levels and urinary excretion of filterable platinum species following bolus injection and iv infusion of cis-dichlorodiammineplatinum (II) in man. Cancer Treat Rep 62: 1359

    Google Scholar 

  23. Salmon SE, Young L, Soehnlen B, Liu R (1984) Antitumor activity of esorubicin in human tumor clonogenic assay with comparisons to doxorubicin. J Clin Oncol 2: 282

    Google Scholar 

  24. Shoemaker RH, Wolpert-DeFilippes MK, Melnick NR, Venditti JM, Simon RM, Kern DH, Lieber MM, Miller WT, Salmon SE, Von Hoff DD (1984) Recent results of new drug screening trials with a human tumor colony forming assay. In: Salmon SE, Trent JM (eds) Human tumor cloning. Grune and Stratton, New York, p 345

    Google Scholar 

  25. Von Hoff DD, Casper J, Bradley E, Trent JM, Hodach A, Reichert C, Makuch R, Altman A (1980) Direct cloning of human neuroblastoma cells in soft agar culture. Cancer Res 40: 3591

    Google Scholar 

  26. Von Hoff DD, Coltman CA, Forseth B (1981) Activity of 9–10 anthracenedicarboxaldehyde bis [(4,5-dihydro-1 H-imidazol-2-yl)hydrazone]dihydrochloride (CL215, 942) in a human tumor cloning system. Leads for phase II trials in man. Cancer Chemother Pharmacol 6: 141

    Google Scholar 

  27. Von Hoff DD, Clark GM, Stogdill BJ, Sarosdy MF, O'Brien MT, Casper JT, Mattox DE, Page CP, Cruz AB, Sandbach JF (1983) Prospective clinical trial of a human tumor cloning system. Cancer Res 43: 1926

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Clinical Chemotherapy, Cancer Chemotherapy Center, Kami-Ikebukuro 1-37-1, Toshima-ku, 170, Tokyo, Japan

    Katsuhiro Inoue, Taketo Mukaiyama, Ikuo Mitsui & Makoto Ogawa

Authors
  1. Katsuhiro Inoue
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Taketo Mukaiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ikuo Mitsui
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Makoto Ogawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Inoue, K., Mukaiyama, T., Mitsui, I. et al. In vitro evaluation of anticancer drugs in relation to development of drug resistance in the human tumor clonogenic assay. Cancer Chemother. Pharmacol. 15, 208–213 (1985). https://doi.org/10.1007/BF00263887

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00263887

Keywords

Search

Navigation